Teva Pharma (TEVA) Tops Q2 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Reports Second Quarter 2023 Financial Results
August 2, 2023 7:00 AM EDTRevenues of $3.9 billion GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56 Cash flow generated from operating activities of $324 million Free cash flow of $632 million AUSTEDO® U.S. revenues of $308 million 2023 revenues outlook revised to $15.0-$15.4 billion from $14.8-$15.4 billion; all other key components reaffirmed: Non-GAAP operating Income of $4.0 $4.4 billion Adjusted EBITDA of $4.5 - $4.9 billion Non-GAAP diluted EPS of $2.25 - $2.55 Free cash flow of $1.7 - $2.1 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE... More
